Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964980 | 0.96 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL14964940 | 0.91 | — | — | |
| SCHEMBL14964922 | 0.80 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL14964968 | 0.79 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL16266967 | 0.78 | ALDH1A1 (0.48) | ALDH1A1POLBHTTKMT2A | |
| SCHEMBL16267043 | 0.77 | KDM4E (0.38) | ALDH1A1HTTKMT2AKDM4E | |
| SCHEMBL14969432 | 0.76 | KDM4E (0.36) | ALDH1A1POLBHTTKMT2AKDM4E | |
| SCHEMBL14964870 | 0.75 | CRHBP (0.44) | — | |
| SCHEMBL14965248 | 0.74 | POLB (0.64) | POLBHTTKMT2A | |
| SCHEMBL14969008 | 0.74 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| EP-2780344-A1 | THIENO [2, 3 - C]PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072693-A1 | THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNK3, KCNJ1 | ALDH1A1 1174/4885POLB 4658/4885HTT 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.